Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.66)
# 4,109
Out of 5,157 analysts
57
Total ratings
30.61%
Success rate
-29.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $4 | $1.95 | +105.13% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $0.26 | +289.11% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $6.12 | +79.74% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $19.45 | +59.38% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.41 | +1,247.52% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $16.78 | +25.15% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.57 | -10.23% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.66 | +863.86% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.36 | +33,233.33% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $33.40 | -25.15% | 2 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $62.79 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $0.95 | +210,448.48% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.62 | +332.10% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.90 | +44.93% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $12.63 | +375.25% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.12 | +435.71% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.62 | +176.24% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.92 | +12,400.00% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $2.40 | +7,483.33% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.92 | +68,393.15% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.71 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.27 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.65 | +117.62% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $8.59 | +122,173.59% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.58 | +1,334.11% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $72.07 | +316.26% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $772.03 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $96.02 | -7.31% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $129.86 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.73 | +19,321.97% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.00 | +260.00% | 1 | Mar 19, 2020 |
Inhibikase Therapeutics
Mar 4, 2026
Initiates: Buy
Price Target: $4
Current: $1.95
Upside: +105.13%
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $0.26
Upside: +289.11%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $6.12
Upside: +79.74%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $19.45
Upside: +59.38%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.41
Upside: +1,247.52%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $16.78
Upside: +25.15%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.57
Upside: -10.23%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.66
Upside: +863.86%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.36
Upside: +33,233.33%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $33.40
Upside: -25.15%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $62.79
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $0.95
Upside: +210,448.48%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.62
Upside: +332.10%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $6.90
Upside: +44.93%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $12.63
Upside: +375.25%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.12
Upside: +435.71%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.62
Upside: +176.24%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.92
Upside: +12,400.00%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $2.40
Upside: +7,483.33%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.92
Upside: +68,393.15%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $12.71
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $9.65
Upside: +117.62%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $8.59
Upside: +122,173.59%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.58
Upside: +1,334.11%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $72.07
Upside: +316.26%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $772.03
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $96.02
Upside: -7.31%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $129.86
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.73
Upside: +19,321.97%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $5.00
Upside: +260.00%